US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...

Nevro Corp. NVRO reported a loss per share of 41 cents in the third quarter of 2024, narrower than the year-ago quarter’s ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

The company announced receiving CE Mark Certification in Europe for its HFX iQ spinal cord stimulation system. Nevro raised ...

Nevro (NYSE:NVRO) announced today that it received CE mark in Europe for its HFX iQ spinal cord stimulation (SCS) system.

Nevro shares surged 21% after better-than-expected revenue in its latest quarter. Shares were trading around $6.44. The stock is down 75% on the year.

Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) also surpassed analyst estimates by 50%. Looking ahead, ...

Baird raised the firm’s price target on Nevro (NVRO) to $6 from $5 and keeps a Neutral rating on the shares. The firm said it remains a show-me story as the business transformation remains underway.

Nevro Corp ( (NVRO) ) has released its Q3 earnings. Here is a breakdown of the information Nevro Corp presented to its investors. Nevro Corp., ...

Nevro (NYSE:NVRO – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, ...

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.

Nevro (NYSE:NVRO) is set to give its latest quarterly earnings report on Monday, 2024-11-11. Here's what investors need to know before the announcement. Analysts estimate that Nevro will report an ...